Medication, Reperfusion Therapy and Survival in a Community-Based Setting of Hospitalised Myocardial Infarction

Download as .RIS

Citation

O'Brien, Emily C.; Rose, Kathryn M.; Suchindran, Chirayath M.; Stürmer, Til; Chang, Patricia P.; Chambless, Lloyd E.; Guild, Cameron S.; & Rosamond, Wayne D. (2013). Medication, Reperfusion Therapy and Survival in a Community-Based Setting of Hospitalised Myocardial Infarction. Heart, 99(11), 767-773. PMCID: PMC4118665

Abstract

Objective: To examine the survival benefit of multiple medical therapies in a large, community-based population of validated myocardial infarction (MI) events.
Design: Retrospective observational cohort study. Setting Population-based sample of 30 986 definite or probable MIs in residents of four US communities aged 35–74 years randomly sampled between 1987 and 2008 as part of the Atherosclerosis Risk in Communities Surveillance Study.
Interventions: None.
Main outcome measures: All-cause mortality 30, 90 and 365 days after discharge.
Results: We used unadjusted and propensity score (PS) adjusted models to examine the relationship between medical therapy use and mortality. In unadjusted models, each medication and procedure was inversely associated with 30-day mortality. After PS adjustment, the crude survival benefits were attenuated for all therapies except for intravenous tissue plasminogen activator therapy (IV-tPA) and stent use. After inclusion of other therapies received during the event in regression models, risk ratio effect estimates (RR; (95% CI)) were attenuated for aspirin (0.66; (0.58 to 0.76) to 0.91 (0.80 to 1.03)), non-aspirin antiplatelets (0.74; (0.59 to 0.92) to 0.92 (0.72 to 1.18)), IV-tPA (0.50; (0.41 to 0.62) to 0.65 (0.52 to 0.80)) and stents (0.53 (0.40 to 0.69) to 0.68 (0.49 to 0.94)). Effect estimates remained stable for all other therapies and were similar for 90- and 365-day mortality endpoints.
Conclusions: We observed inverse associations between receipt of six medications and procedures for MI and all-cause mortality at 30, 90 and 365 days after adjustment for PS. The mortality benefits observed in this population-based setting are consistent with those reported in clinical trials.

URL

http://dx.doi.org/10.1136/heartjnl-2012-303244

Reference Type

Journal Article

Year Published

2013

Journal Title

Heart

Author(s)

O'Brien, Emily C.
Rose, Kathryn M.
Suchindran, Chirayath M.
Stürmer, Til
Chang, Patricia P.
Chambless, Lloyd E.
Guild, Cameron S.
Rosamond, Wayne D.

PMCID

PMC4118665

ORCiD

Suchindran - 0000-0002-5087-7762